AI scribes have been one of the hottest areas in healthcare, raising $1.6 billion so far this year alone. But as health IT giants like Epic roll out their own versions …
Madrigal CEO welcomes MASH competition from Novo as demand climbs higher for Rezdiffra
Madrigal Pharmaceuticals CEO Bill Sibold doesn’t seem worried about sharing the MASH market with Novo Nordisk’s blockbuster GLP-1 drug. In an interview with Endpoints News

